Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-89402638
- Development stage
- Phase 1
- Lead developer
- Janssen Research & Development
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
JNJ-89402638 is an investigational bispecific antibody developed by Janssen Research & Development (a Johnson & Johnson company) for the treatment of unresectable metastatic colorectal cancer. The drug is currently in Phase 1 clinical trials, where its primary objectives are to determine the recommended Phase 2 dose and assess safety in patients who have progressed after at least two prior lines of standard therapy. Mechanistically, JNJ-89402638 acts as an inhibitor targeting both ENPP3 and CD3, suggesting it may function by redirecting T cells to tumor cells expressing ENPP3 through engagement with CD3 on T cells[7][2][5]. The precise molecular details and full mechanism of action have not been publicly disclosed.
02
Targets
ENPP3 (Ectonucleotide pyrophosphatase/phosphodiesterase 3)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on JNJ-89402638.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-89402638.